Altimmune, Inc. Stock News

ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while at the current rate, but not to fund phase 3, the company needs a partner or a buyout. If ALT can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock.

Altimmune (ALT 3.54%) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized stock index; investors greeted this news by trading the company's stock up by more than 3% on the day.

GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024.

Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety profile. Altimmune is redefining success in both obesity and MASH to position Pemvidutide in "blue ocean" categories not addressed by incumbents and catered to the unique strengths of Glucagon in P...

GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids

Results from the phase 2b IMPACT study, using Pemvidutide for the treatment of patients with MASH, expected Q2 of 2025. The global metabolic dysfunction-associated steatohepatitis market size is expected to reach $7.64 billion by 2031. Successful EOP2 meeting with FDA, of Pemvidutide for treatment of patients with obesity, brings about four phase 3 trial initiations in the coming year.

Altimmune, Inc.'s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obesity demonstrated significant weight loss and lean mass preservation, with up to 15.6% weight reduction at the highest dose. Altimmune's cash runway is estimated to support operations into 1H2026, ...